| abstract |
The present invention relates to acyl coenzyme A: a novel compound that is an inhibitor of diacylglycerol acyltransferase 1 (DGAT-1), a pharmaceutical composition containing the same, a method for preparing the same, and the regulation of DGAT-1 activity or associated with DGAT-1 dysfunction. It relates to the use of such compounds in therapy alone or in combination with weight management therapy or other triglyceride lowering therapy for the prevention or treatment of diseases that may have this therapeutic benefit. |